Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Веза се чува у привремену меморију
СтатусЗавршено
Спонзори
Mutual Pharmaceutical Company, Inc.

Кључне речи

Апстрактан

The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and sprinkled on applesauce (1 tablespoon) relative to the same dose given as an intact tablet to healthy subjects following an overnight fast. A secondary objective is to evaluate the safety and tolerability of this regimen in healthy volunteers. All study subjects will be monitored for adverse events throughout the study period.

Опис

The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and sprinkled on applesauce (1 tablespoon) relative to the same dose given as an intact tablet to healthy subjects following an overnight fast. Sixteen healthy, non-smoking, non-obese, male and female volunteers between 18-55 years of age will be randomly assigned in a crossover fashion to receive each of two dosing regimens in sequence with a 14 day washout period between dosing periods. In each of the dosing periods, after an overnight fast, subjects will receive one intact Colcrys® 0.6 mg tablet (followed by 240 mL of water) or one Colcrys® 0.6 mg tablet crushed and sprinkled on 1 tablespoon of applesauce (followed by 240 ml of water) according to the randomization schedule. Blood samples will be drawn from all participants before dosing and for 48 hours post-dose at times sufficient to adequately define the pharmacokinetics of colchicine. Vital signs (blood pressure, heart rate, respiratory rate and temperature) will be measured prior to dosing, 1 hour ± 30 minutes post-dose and upon discharge from the clinical facility. Subjects will be monitored throughout their participation in the study for adverse reactions.

Датуми

Последња верификација: 04/30/2011
Фирст Субмиттед: 05/20/2010
Предвиђена пријава послата: 05/23/2010
Прво објављено: 05/24/2010
Послато последње ажурирање: 05/09/2011
Последње ажурирање објављено: 05/11/2011
Датум првог достављања резултата: 04/04/2011
Датум првог подношења резултата КЦ: 04/04/2011
Датум првог објављивања резултата: 05/10/2011
Стварни датум почетка студије: 04/30/2010
Процењени датум примарног завршетка: 05/31/2010
Предвиђени датум завршетка студије: 05/31/2010

Стање или болест

Healthy

Интервенција / лечење

Drug: Colcrys® 0.6 mg intact tablet

Drug: Colcrys® 0.6 mg tablet on applesauce

Фаза

Фаза 1

Групе руку

АрмИнтервенција / лечење
Experimental: Colcrys® 0.6 mg intact tablet
One Colcrys® 0.6 mg intact tablet taken by mouth
Drug: Colcrys® 0.6 mg intact tablet
One Colcrys® 0.6 mg intact tablet taken by mouth
Experimental: Colcrys® 0.6 mg tablet on applesauce
One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
Drug: Colcrys® 0.6 mg tablet on applesauce
One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce

Критеријуми

Узраст подобан за студирање 18 Years До 18 Years
Полови подобни за студирањеAll
Прихвата здраве волонтереда
Критеријуми

Inclusion Criteria:

- Healthy adults age 18-55, non-smoking, non- pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) with a body mass index of 18-30 kg/m²

Exclusion Criteria:

- Recent participation (within 30 days) in other research studies

- Recent significant blood donation or plasma donation

- Pregnant or lactating

- Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)

- History of treatment for drug or alcohol addiction within the previous 12 months or use of tobacco products within 90 days of the start of the study

- Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction, especially cardiovascular disorders (angina, heart failure, irregular heartbeats, heart attack, hypertension, hypotension) stroke, renal or hepatic disorders, diabetes or bleeding disorders, gastrointestinal disease or history of malabsorption within the last year

- History of psychiatric disorders occurring within the last two years that required hospitalization or medication

- Presence of a medical condition requiring regular treatment with prescription drugs

- Use of any drugs or substances known to inhibit or induce drug-metabolizing enzymes within 30 days prior to dosing with the study drug

- Drug allergies or sensitivity to colchicine

- Positive test results for drugs of abuse at screening

Исход

Примарне мере исхода

1. Maximum Plasma Concentration (Cmax) [serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.25, 0.5, 1.0, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 18, 20, 24, 36, and 48 hours after drug administration]

The maximum or peak concentration that Colcrys® reaches in the plasma

2. Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] [serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.25, 0.5, 1.0, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 18, 20, 24, 36, and 48 hours after drug administration]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable Colcrys® concentration (t), as calculated by the linear trapezoidal rule

3. Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] [serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.25, 0.5, 1.0, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 18, 20, 24, 36, and 48 hours after drug administration]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC (0-∞) was calculated as the sum of AUC (0-t) plus the ratio of the last measurable Colcrys® plasma concentration to the elimination rate constant.

Придружите се нашој
facebook страници

Најкомплетнија база лековитог биља подржана науком

  • Ради на 55 језика
  • Биљни лекови потпомогнути науком
  • Препознавање биљака по слици
  • Интерактивна ГПС мапа - означите биље на локацији (ускоро)
  • Читајте научне публикације повезане са вашом претрагом
  • Претражите лековито биље по њиховим ефектима
  • Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима

Google Play badgeApp Store badge